Trial Profile
A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Crenolanib (Primary) ; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors AROG Pharmaceuticals
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 17 Jul 2020 Status changed from active, no longer recruiting to completed.
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association